The patent expires in 2028 and covers methods of inhibiting inflammation by means of intravenous immunoglobulin (IVIG)-derived, sialylated Fc regions.
Momenta president and chief executive officer Craig Wheeler said the US patent was the first to be issued from a patent family related to sialylated Fc-containing products.
"Obtaining patent protection for sialylated Fc-containing products, whether recombinant or derived from IVIG, is an important strategic priority in our development of this exciting new technology, and we expect to expand the patent protection afforded by this licensed patented family," Wheeler added.
Momenta is developing the sialylation technology and applying it in the development of novel medicines for autoimmune and inflammatory diseases.